Comparative Biosciences, Inc. (CBI), a leading preclinical Contract Research Organization (CRO), has demonstrated expertise in all phases of the drug development process in preclinical contract dermal toxicology studies. Due to CBI’s unique and extensive experience in preclinical contract dermatology studies and state-of-the-art facilities, we have the skill and expertise to accelerate new dermatology drugs, small molecules, biologics, stem cells, nanoparticles, and devices from discovery through the drug development process, to regulatory submission and studies in man.
Dermal toxicology study expertise at CBI includes:
- Skin irritation studies to intact or abraded skin
- Acute (LD50) dermal toxicity study in rats or rabbits
- Acute single or multiple dose dermal toxicity studies in rodents
- Acute single or multiple dose dermal toxicity studies in minipig or other nonrodent species
- Two week dermal toxicity studies in rodents
- Two week dermal toxicity studies in minipig or other nonrodent
- Four week dermal toxicity studies in rodents (with or without recovery period)
- Four week dermal toxicity studies in minipig or other nonrodent(with or without recovery period)
- 3, 6, or 12 month dermal toxicity studies in rodents (with or without recovery period)
- 3, 6, or 12 month dermal toxicity studies in minipig or other nonrodent(with or without recovery period)
- Two year oncogenicity dermal studies in rodents and nonrodents
- Co-carcinogenicity dermal studies in rodents and nonrodents
- Acute perivascular irritation study in rabbits
- Hypersensitization studies